Search Publications

The Aerogen nebulizers provide superior aerosol therapy within the intensive care environment during ventilation, NIV, NHF and is now available for use with spontaneously breathing patients.

Changing from an open mask to the mouthpiece with the Aerogen Ultra resulted in a rapid clinical response.

During infant ventilation with bias flow, more than 2 fold more drug is delivered when placed at the wye compared to the humidifier

A lung dose of 10.6% is achievable at a flow rate of 10L/min. Lower flow rates correlate with higher drug deposition.

Lung dose was six times higher with the Ultra (34.1%) vs Jet Neb (5.2%)

Using Aerogen provides similar aerosol deposition as standard treatment with the added benefit of providing high flow therapy at the same time

-Actual lung deposition of 10-15% when AErogen Solo is placed at the wye with bias flow during ventilation -Higher aerosol deposition with volume vs pressure controlled ventilation

Aerogen Solo outperforms SVNs when positioned proximal to the patient in adult, pediatric and infant models

Change to Aerogen Solo  from MDIs resulted in a 3-month savings of $99,359 in drug cost and an extrapolated full-year savings of $397,436.

The Aerogen Solo  delivered a greater inhaled mass than a pMDI or SVN during pediatric ventilation through a tracheostomy

Aerogen deposited significantly more drug in the lungs at the lower flow rate of 30 l/min vs 45 l/min and 60 l/min

Aerogen Solo nebulization during Nasal High Flow was better tolerated than a standard jet nebulizer with aerosol mask.

Retrospective study showing significantly improved outcomes for all patients requiring albuterol in the ED when delivery was via Aerogen Ultra compared to standard jet nebulizers:

• 32% reduction in admissions
• 30% higher discharges from the ED
• 37 minute reduction in median length of stay
• 75% reduction in albuterol dose

Significant improvement in lung function (FVC) with an accompanied improvement in patient’s breathlessness score during COPD exacerbation with just a single 2.5mg salbutamol dose delivered with the Aerogen Ultra.

The Aerogen Solo delivered a significantly great amount of aerosol (P-values <0.05) when compared to a jet nebuliser  for all positions evaluated (dry side of the humidifier and at tracheostomy tube) during spontaneously breathing and mechanical ventilation in tracheostomy patients.

Aerosol emissions are greatly reduced with the use of a mouthpiece and valved facemask when used with the Aerogen Ultra

Aerogen aerosol devices deliver more aerosols than SVNs and ultrasonic nebulizers. .

A performance improvement plan including the use of noninvasive methods of ventilatory support and efficient advanced aerosol techniques using the Aerogen Solo had a positive impact on clinical outcomes, as well as staff and patient satisfaction

Aerosol therapy using the NIVO nebulizer resulted in 3 fold higher pulmonary deposition than a JET nebulizer during non-invasive ventilation 

4 fold more lung dose was achieved with the Ultra compared to a jet neb

Changing from an open to a valved mask with Aerogen Ultra improved lung dose, reduced aerosol loss, improved patient clinical response and improved patient satisfaction.

Improved  Functional residual capacity (FRC) by 18.3% after bronchodilator treatment using Aerogen Solo.

Aerogen achieved optimal drug delivery via HFNC, SiPAP and bubble CPAP when positioned dry side of the humidifier

The Aeroneb Solo outperformed the small volume nebulizer with all humidification systems in a simulated tracheostomy patient

The Aerogen Ultra is faster and more effective than a jet nebuliser, delivering more salbutamol over a shorter period of time.

In spontaneous breathers the Aeroneb Solo Adapter achieves 4.5 fold higher inhaled dose than a standard small volume nebulizer

"We have formally adopted the Aeroneb Solo device as the nebuliser of choice in our clinical sputum induction program at the University of Calgary"

Increased albuterol was delivered in a lung model with the NIVO nebulizer which is placed in the mask and therefore after the exhalation valve

The Aeroneb Solo performance was superior to small volume nebulizers regardless of the position in the ventilator circuit

Effective aerosol delivery can be achieved during infant variable flow NCPAP

Lung dose during Nasal High Flow is comparable to those reported in the literature with vibrating mesh nebulizers during both invasive and non-invasive mechanical ventilation.

Substantial cost savings have been acknowledged after transition from MDIs to the Aerogen Solo used during ventilation in 13 long term acute care hospitals

Cost per patient was reduced to $46 from $191 after transition from MDI to the Aeroneb Solo during ventilation. Potential (105 hospitals) implementation could lead to annual savings from $870,000 - $1,740,000

Conversion from MDI to Aeroneb Solo resulted in significant cost savings and no change in clinical outcomes or staff satisfaction

The NIVO achieved the highest Respirable Dose of the three aerosol generators tested across both adult and paediatric CPAP and NIPPV settings

Aerosol therapy during mechanical ventilation is used by more than 95 % of intensivists mainly to deliver bronchodilators and steroids. A breakdown of the drugs and nebulisers used worldwide is presented.

The Aeroneb Pro was used to relieve bronchospasm in an intubated 3-year-old girl after MDI and jet nebulizers were unsuccessful.

Aerosol delivery during Nasal High Flow is more efficient than the RAM cannula in a simulated neonatal lung model

The Aeroneb Solo delivered four fold more aerosolized medication than a jet nebulizer during simulated mechanical ventilation

The Aeroneb Pro and Aeroneb Solo have a greater emitted/inhaled dose compared to a Jet Nebulizer in a simulated adult model of non-invasive ventilation. Dose increased with both nebulizers positioned on the patient side of the exhalation/leak port

In a Neuroscience ICU, adoption of Aeroneb Solo resulted in a 22% reduction in ICU length of stay and a trend in reduced ventilator days

In vitro model of CPAP and non-invasive ventilation demonstrated increased inhaled mass with the NIVO compared to a small volume nebulizer. The NIVO treatment time was also reduced and minimal residual volume was observed

Efficient delivery of aerosol is observed during Nasal High Flow, where aerosol delivery is higher at lower flows. Heliox improves aerosol deposition at higher flows.

Clinical outcomes were similar after a change in practice from MDI to the Aeroneb Solo. There was a $57,854.24 cost reduction after implementation of Aeroneb Solo

Jet nebulizers are less efficient than the Aeroneb Solo or pMDI in a simulated model of non-invasive ventilation. The Aeroneb Solo had a significantly lower residual volume than the jet nebulizer

A urinary pharmacokinetic method of drug excretion was used to show the performance of the Aeroneb Pro and a jet nebuliser during non-invasive ventilation with COPD patients. The Aeroneb Pro was deemed the more efficient nebuliser.

Inhaled dose was greater for the Aeroneb Pro than the jet nebulizer when positioned both patient side and ventilator side of the leak port. The respirable dose is significantly higher when the nebulizer is positioned patient side of the leak port

The mean inhaled dose delivered by the Aeroneb Solo was 3-fold greater than a jet nebulizer with a heated and humidified mechanical ventilation circuit

The mean inhaled dose delivered by the Aeroneb Solo was 2–3-fold greater than the jet nebulizer during simulated mechanical ventilation

Editorial discussing Arzu Ari publications on aerosol therapy during mechanical ventilation

The Aeroneb Solo nebulizer is more efficient than the Mistyneb Jet Nebulizer during neonatal simulated mechanical ventilation

An in vitro model of aerosol delivery with the Aeroneb Solo and Nasal High Flow demonstrated increased aerosol delivery with heliox and with decreasing flow

The Aeroneb Solo nebulizer is more efficient than the Mistyneb Jet Nebulizer during adult simulated mechanical ventilation

Case study of a ventilated pediatric patient with severe asthma treated with albuterol using the Aeroneb Solo

In vitro aerosol therapy can be effectively delivered non-invasively with Nasal High Flow and the Aeroneb Solo

~25-fold greater lung deposition with the Aeroneb Pro compared to a Jet nebulizer (MistyNeb) in an neonatal animal model of mechanical ventilation

Review of aerosol delivery to ventilated infant and pediatric patients

The Aeroneb Pro delivered more albuterol during high frequency oscillation compared with 2 jet nebulizers

Case study of the use of the Aeroneb Solo during Nasal High Flow to deliver albuterol to a severe asthmatic patient